Search Results
Search results for "Glaxo Inc"
Results found for "Glaxo Inc"
- Dr. Terry Kenakin | Dr. GPCR Ecosystem
Kenakin joined Glaxo Inc in RTP where he remained for 25 years through iterations of Glaxo Inc, GlaxoWellcome
- Foord: Serendipity, RAMPs, And Industrial GPCR Pharmacology | Dr. GPCR Ecosystem
path from academic neuroendocrinology to introducing molecular biology and molecular pharmacology into Glaxo Foord is a physiologist and pharmacologist who spent more than two decades at Glaxo, Glaxo Wellcome, contributed to the identification of RAMPs in the CGRP receptor system, deorphanization of several GPCRs including and practical considerations in choosing receptor-rich tissues. 05:00 — Transition from academia to Glaxo
- Receptor Signaling Bias: A Valuable and Accessible Property of New Drug Candidates | Dr. GPCR Ecosystem
He spent 25 years in drug discovery at Glaxo (now GlaxoSmithKline) before joining UNC Chapel Hill, where with leading pharma and biotech companies. 1,500 human GPCR products covering ~90% of the GPCR-ome, including
- Tuning GPCR System Sensitivity: Revealing True Drug Activity Through Functional Volume Control | Dr. GPCR Ecosystem
measure affinity and relative efficacy and turn low-efficacy agonists into measurable antagonists, how increasing sensitivity uncovers efficacy hidden in apparently neutral compounds, and how greatly increasing it The same approach distinguishes what an allosteric modulator does to affinity versus efficacy, including He spent 25 years in drug discovery at Glaxo, now GlaxoSmithKline, before joining UNC Chapel Hill, where with leading pharma and biotech companies. >1,500 human GPCR products covering ~90% of the GPCR-ome, including
- Scott Struthers | Dr. GPCR Ecosystem
Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc he initiated and led the effort to discover and develop orally active, nonpeptide GnRH antagonists, including Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions
- Dr. Josephine (Pina) Cardarelli | Dr. GPCR Ecosystem
Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. Prior to this, she held the position of Vice President, at Medarex, Inc . While at BMS and Medarex, she led programs from target ID to clinical development that included, CXCL10 She is an inventor on 39 issued U.S. patents including anti-PD-1 patents, 22 EP patents, and greater
- Steve McCloskey | Dr. GPCR Ecosystem
After graduating from UCSD he founded Nanome Inc to build Virtual Reality solutions for Scientists and
- Dr. Josh Pottel | Dr. GPCR Ecosystem
Josh Pottel "I lead Molecular Forecaster Inc.
- Dr. Juan José Fung | Dr. GPCR Ecosystem
Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused
- Dr. Patrick Sexton | Dr. GPCR Ecosystem
Sexton’s awards include the Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists Sexton is also a co-founder of the San Francisco-based biotechnology company Septerna Inc . Dr.
- Dr. Bruno Giros | Dr. GPCR Ecosystem
doctoral training at the Pierre and Marie Curie University in Paris and a short internship at Genentech Inc with an H factor of 79 and 32,000 citations (Google Scholar) and has received several distinctions, including
- Recombinant Antibodies for GPCRs: A Challenge to the Community | Dr. GPCR Ecosystem
platform was built, what it takes to produce specific antibodies against multipass transmembrane targets including Alexander Ball , MD, Senior Scientist, GeneTex, Inc. Dr.
- GPCR Masterclass Live Courses | Dr. GPCR Ecosystem
Masterclass is included inDr. Masterclass is included in Dr.
- GPCR Webinars | Dr. GPCR Ecosystem
activity, inverse agonism How volume control reveals essential properties of allosteric modulators, including
- Terry Hébert | Dr. GPCR Ecosystem
remotely; the continuity of receptor pharmacology work already in the pipeline before the shutdown, including
- David Gloriam: Orphan Receptors, GPCRDB, and the Data Revolution in GPCR Pharmacology | Dr. GPCR Ecosystem
His group contributed to the de-orphanization of GPR139 and GPR55, including the identification of sub-nanomolar
- Self-Learning, Collaboration, and Delegation in Science with Dr. Badr Sokrat | Dr. GPCR Ecosystem
Badr worked in various science labs, including Dr. Christian Badr’s and Dr.
- Jacob Lee and Jin Cho: Rebuilding the Software Layer Under Modern Research | Dr. GPCR Ecosystem
One day as they were catching up, Jacob shared his struggles of managing samples and an incredible amount
- Dr. Arthur Christopoulos | Dr. GPCR Ecosystem
novel paradigms of drug action at GPCRs, particularly allosteric modulation and biased agonism, and incorporates Professor Christopoulos has over 360 publications, including in leading international journals such as He has also been the recipient of multiple awards, including the John J. They shared their unconventional approaches to research, including the creation of a critical mass of The conversation highlighted ongoing challenges within universities, including resistance to change and
- Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem
GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems Fluorescent tools for imaging endogenous incretin receptors across biological systems Interrogating Incretin Receptor Biology Across Biological Complexity localization, nanodomain organization, and functional engagement within complex biological systems remain incompletely His group focuses on the development of chemical tools — including fluorescent ligands and photopharmacological glucose homeostasis, food intake regulation, and inflammation — within complex tissue environments including
- Eleonora Comeo: Fluorescent Ligands and the Pharmacology of Adenosine Receptors | Dr. GPCR Ecosystem
framework does not address Adenosine receptors form both homodimers and heterodimers with other GPCRs, including The advice she offers to incoming PhD students centers not on technique but on disposition: stay curious
- Dr. Davide Calebiro | Dr. GPCR Ecosystem
His major scientific contributions include the discovery that GPCRs are not only active at the plasma He has served on multiple panels and committees, including the ENDO Annual Meeting Steering Committee
- Chemical Probes for GPCR Imaging and Internalization with Dr. Johannes Broichhagen | Dr. GPCR Ecosystem
His postdoctoral training included research at the École Polytechnique Fédérale de Lausanne (2015–2016
- Robert J. Lefkowitz: Beta-Adrenergic Receptors, the GPCR Family, and Fifty Years of Discovery | Dr. GPCR Ecosystem
Lefkowitz committed to receptor research in the early 1970s, prominent pharmacologists, including Raymond
- Aaron Sato: Synthetic Antibody Libraries for the Hardest GPCR Targets | Dr. GPCR Ecosystem
already failed — not because the biology is easier, but because new technology is rewarded most where the incumbents an opportunity to tackle the challenge of identifying novel functional antibodies targeting GPCRs by incorporating
- Dr. Michael Feigin | Dr. GPCR Ecosystem
Scientific Journey and Drug Discovery Challenges Mike shared significant moments in his scientific journey, including
- Masha Niv: Bitter Taste Receptors and the Drug Discovery Blind Spot | Dr. GPCR Ecosystem
distinction opened space for a more nuanced view of bitter compounds in nutrition and pharmacology - including screen extensively for efficacy, safety, and pharmacokinetics - but bitterness prediction was rarely incorporated
- Dr. Richard Premont | Dr. GPCR Ecosystem
) and arrestins as GPCR regulators and as mediators of distinct signaling pathways through partners including In our work, we utilize methods including structural biology and proteomics, molecular biology and biochemical
- Scaling GLP 1 Receptor Tools Through Academia Industry Collaboration | Dr. GPCR Ecosystem
She earned her PhD in medicinal chemistry from the University of Bari in 2018, including research training His research focuses on class B GPCRs, including the GLP-1 and GIP receptors, with an emphasis on understanding
- Pod-Be Our Guest - Public | Dr. GPCR Ecosystem
we have recorded and released over 156 episodes and hosted GPCR specialists from all over the world, includingDr Marc Caronwith over 30 guests includingDr. Kathleen Caron, Dr.
























